What is DermaSensor?
DermaSensor is at the forefront of dermatological innovation, developing an FDA-cleared device that utilizes AI for the non-invasive assessment of suspicious skin lesions. This technology enhances diagnostic accuracy and streamlines the screening process, enabling healthcare professionals in various fields, including internal medicine, family medicine, and medical aesthetics, to make more timely and confident decisions. By improving clinical confidence and offering point-of-care solutions, DermaSensor aims to significantly impact early skin cancer detection and patient outcomes.
How much funding has DermaSensor raised?
DermaSensor has raised a total of $16M across 1 funding round:
Series B
$16M
Series B (2025): $16M with participation from Kern Venture Group, Pier 70 Ventures, and GenHenn Capital
Key Investors in DermaSensor
Kern Venture Group
Kern Venture Group is a venture capital firm based in California that focuses on bridging gaps and fostering innovation, particularly in early-stage to Series B investments within aerospace, defense, energy, agriculture, and healthcare.
Pier 70 Ventures
Pier 70 Ventures invests in impact-driven technologies, especially in healthcare, providing capital, mentorship, and a global network to accelerate high-growth sustainable companies.
GenHenn Capital
GenHenn Capital is a venture capital firm focused on early-stage life sciences, healthcare, and biotech companies, providing capital and strategic guidance with a typical investment of $2-5 million per company.
What's next for DermaSensor?
With the recent influx of major strategic investment, DermaSensor is poised for an accelerated growth phase. This capital infusion is anticipated to fuel further research and development, expand its commercial reach, and enhance its AI-driven diagnostic platform. The company's focus on improving healthcare provider confidence and patient outcomes through accessible technology positions it for substantial market impact. Future developments will likely involve broader adoption across diverse medical practices and continued refinement of its precision screening capabilities, solidifying its position in the health-tech landscape.
See full DermaSensor company page
